[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-344423-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-344423-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","bright-side-of-the-dark-genome-antigens-for-next-gen-cancer-vaccines","Bright side of the dark genome: antigens for next-gen cancer vaccines","","The discovery of cancer’s hidden antigen landscape—comprising non-canonical ‘dark matter’ antigens—reveals a broad pool of immune targets for next-generation cancer immunotherapy. Unlike many neoantigen vaccine approaches that miss most predicted neoepitopes presented by tumor HLA molecules, noncanonical peptides from open reading frames, aberrant splice products, and non-coding RNAs derived from SLiPs are stabilized in class I HLA and show strong immunogenicity. Shared immunopeptides may also influence tumor biology. This framework supports off-the-shelf vaccines and motivates revisiting shared tumor antigens to overcome neoantigen-focused limitations.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/bright-side-of-the-dark-genome-antigens-for-next-gen-cancer-vaccines/344423/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/bright-side-of-the-dark-genome-antigens-for-next-gen-cancer-vaccines/344423.png","ImageObject",300,407,{"name":42,"@type":43},"Valentina","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-16","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",11,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is the main focus of this review?","Question",{"text":63,"@type":64},"It examines how hidden, non-canonical “dark matter” antigens broaden immune targets for next-generation cancer vaccines, and how new technology reshapes established views of cancer immunotherapy.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"Why might many neoantigen vaccine trials have produced negative results?",{"text":68,"@type":64},"Sensitive mass spectrometry studies often fail to detect the majority of predicted neoepitopes actually presented by tumor HLA molecules, which may undermine neoantigen-focused strategies.",{"name":70,"@type":61,"acceptedAnswer":71},"What makes SLiP-derived noncanonical peptides promising for vaccines?",{"text":72,"@type":64},"Peptides from noncanonical open reading frames, splice products, and non-coding RNAs associated with short-lived proteins are stabilized in class I HLA and can be strongly immunogenic, including being frequently undetected in the thymus.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},344423,1790463644,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":140,"language":141,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":12,"update_tm":145,"read_time":146,"preview_page_count":33,"preview_urls":147},13056703020460,"https://ap-avatar.wpscdn.com/avatar/be000253dac470eee5d?_k=1778207105932848923","Open access Review  \n Bright side of the dark genome: antigens for next-gen cancer vaccines  \nXiao-Song Wang  ,1,2 Bernard A Fox  3,4  \nTo cite: Wang X-S, Fox BA. Bright side of the dark genome: antigens for next-gen cancer vaccines. Journal for ImmunoTherapy of Cancer 2026;14:e014075 . doi:10 . 1136/ jitc-2025-014075  \n► Additional supplemental material is published online only. To view, please visit the journal online ([https://doi.org/10.1136/](https://doi.org/10.1136/)[ ](https://doi.org/10.1136/)[jitc-2025-014075](jitc-2025-014075)) .  \nAccepted 20 January 2026  \nWatch Video  \n[https://jitc.bmj.com](https://jitc.bmj.com)  \n© Author(s) (or their employer(s)) 2026. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ Group.  \n1UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, Pennsylvania, USA 2Department of Pathology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA 3Earle A. Chiles Research Institute, Robert W. Franz Cancer Center, Providence Cancer Institute, Portland, Oregon, USA 4Department of Molecular Microbiology and Immunology, and Knight Cancer Institute, Oregon Health and Science University, Portland, Oregon, USA  \nCorrespondence to  \nDr Xiao-Song Wang; [xiaosongw@pitt.edu](xiaosongw@pitt.edu)  \nDr Bernard A Fox;  \n[bernard.fox@providence.org](bernard.fox@providence.org)  \nABSTRACT  \nThe discovery of cancer’s hidden antigen landscape—comprising non-canonical ‘dark matter’ antigens—has unveiled a vast, untapped reservoir of immune targets for next-generation cancer immunotherapy. While most cancer vaccine strategies of the past decade have focused on mutation-derived neoantigens, studies applying sensitive mass spectrometry methods fail to identify the majority of predicted neoepitopes being presented by tumor human leukocyte antigen (HLA) molecules, potentially explaining negative results of several recent neoantigen vaccine trials. By contrast, peptides from noncanonical open reading frames, aberrant splice products, and non‐coding RNAs that derive from short-lived proteins (SLiPs) are readily stabilized in class I HLA, and as a consequence of frequently being undetected in the thymus, have demonstrated strong immunogenicity. Early reports suggest some non-canonical immunopeptides are shared within and sometimes across multiple cancer histologies, with early evidence that some have tumorpromoting functions. Because these SLiPs are degraded so quickly and are stabilized in HLA-I, the intact proteins are postulated to not be accessible to antigen-presenting cells and are not efficiently processed and cross-presented—positioning this ‘junk DNA’—derived antigen class as an attractive foundation for off-the-shelf vaccines. Here, wetrace four phases of cancer vaccine evolution, review the technological advances that enabled the discovery of the dark immunopeptidome and discuss how these findings challenge established paradigms and reinvigorate interest in shared tumor antigens. By embracing this expanded antigenic universe, the field is poised to overcome key limitations of neoantigen-focused immunotherapy and move toward more universally effective cancer vaccines.  \nFor the graphical abstract of this paper see figure 1.  \nINTRODUCTION  \nPhase I: whole tumor cell vaccines and their derivatives  \nThe first generation of modern cancer vaccines emerged in the 1960s and centered around whole tumor cell approaches. Early studies involved transferring tumor fragments between patients to prime lymphocytes, which were then adoptively transferred back to the host.1 Other strategies used whole-cell vaccines alone or combined with adjuvants or  \npurified antigens such as GM2 gangliosides, with signs of immunogenicity and occasional clinical effects that commonly coincided with immune evidence.2–6  \nA major breakthrough came with the demonstration that tumor cells engineered to secrete granulocyte-macrophage colonystimulating factor (GM-CSF) significantly enhan","cbCaibDO0Xf92jUi","https://ap.wps.com/l/cbCaibDO0Xf92jUi","pdf",1500124,17,"English","# Introduction\n## Phase I: whole tumor cell vaccines and their derivatives\n## Figure 1: Graphical abstract","[{\"question\":\"What is the main focus of this review?\",\"answer\":\"It examines how hidden, non-canonical “dark matter” antigens broaden immune targets for next-generation cancer vaccines, and how new technology reshapes established views of cancer immunotherapy.\"},{\"question\":\"Why might many neoantigen vaccine trials have produced negative results?\",\"answer\":\"Sensitive mass spectrometry studies often fail to detect the majority of predicted neoepitopes actually presented by tumor HLA molecules, which may undermine neoantigen-focused strategies.\"},{\"question\":\"What makes SLiP-derived noncanonical peptides promising for vaccines?\",\"answer\":\"Peptides from noncanonical open reading frames, splice products, and non-coding RNAs associated with short-lived proteins are stabilized in class I HLA and can be strongly immunogenic, including being frequently undetected in the thymus.\"}]","Bright side of the dark genome: antigens for next-gen cancer vaccines | PDF",1790053718,43,[148,152,156,160],{"page_no":22,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6ebbc2e9c998f9c6263509ee09efc686.webp",983,1310,{"page_no":26,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c612f157513715a1647e192d1edc879d.webp",982,1309,{"page_no":30,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/dd1bde5483f57d33fd7bfee90217474c.webp",981,1308,{"page_no":33,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d89ee47c0c6de0c19dd095e7255c892c.webp",980,1306]